New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
March 24, 2025 – Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical – Amarin Corp, American College of Cardiology, cardiovascular events, conferences and events, eicosapentaenoic acid
19 March 2025 — Dublin, Ireland & New Jersey, US — Amarin Corporation plc today announced that additional in vitro mechanistic data with eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology’s Annual Scientific Session & Expo, March 29-31, 2025, in Chicago, IL.
“At Amarin, we continue to invest in the science behind VASCEPA/VAZKEPA to further explore the potential mechanistic activities of EPA, administered clinically in the form of our icosapent ethyl product, to reduce cardiovascular (CV) events in at-risk patients,” said Steve Ketchum, EVP, President of R&D and Chief Scientific Officer at Amarin. ”With the advancement of additional therapeutic agents targeting other biological pathways and other domains of residual CV risk, Amarin’s research funding and scientific efforts become even more important. There may be additional biological benefits – via overlapping or distinct protective mechanisms – when combining EPA with emerging therapies like GLP-1 receptor agonists, which have been clearly shown to reduce CV risk on top of LDL-C lowering statin therapy,” added Ketchum.
“The data being presented at ACC.25 will provide further in vitro mechanistic evidence on the biological activities of EPA, specifically on the antioxidant effects of EPA on lipoprotein(a) [Lp(a)]-enriched plasma and on the effects of a GLP-1 receptor agonist in combination with EPA on the expression of antioxidant proteins in endothelial cells during inflammation,” concluded Ketchum.
Featured Amarin-supported abstracts to be presented by international academic collaborators at ACC Scientific Sessions 2025 include:
Moderated Poster Presentations
- More Rapid Oxidation of Lipoprotein(a) [Lp(a)]-enriched Plasma Compared to Small Dense- and Triglyceride-rich Lipoproteins is Limited by Eicosapentaenoic Acid (EPA)
Samuel C.R. Sherratt, PhD, Peter Libby, MD, Richard L. Dunbar, MD, Deepak L Bhatt, MD, MPH, MBA, R. Preston Mason, PhD, MBA
– Available March 29th, 11:30am ET
– Moderated Poster Theater 2 - Addition of Eicosapentaenoic Acid (EPA) to a GLP-1 Agonist Enhanced Expression of Detoxification Proteins in Endothelial Cells During Inflammation in Vitro
Samuel C.R. Sherratt, PhD, Peter Libby, MD, Richard L. Dunbar, MD, Deepak L Bhatt, MD, MPH, MBA, R. Preston Mason, PhD, MBA
– Available March 29th, 11:42am ET
– Moderated Poster Theater 2
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. Visit: www.amarincorp.com.
